CYCLOSPORINE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cyclosporine, and what generic alternatives are available?
Cyclosporine is a drug marketed by Apotex, Dr Reddys Labs Sa, Ivax Sub Teva Pharms, Sandoz, Strides Pharma, Deva Holding As, Mylan, Saptalis Pharms, Teva Pharms Usa Inc, Hikma, Padagis Us, Abbvie, Pharm Assoc, and Pharmobedient Cnsltg. and is included in eighteen NDAs.
The generic ingredient in CYCLOSPORINE is cyclosporine. There are eighteen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the cyclosporine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cyclosporine
A generic version of CYCLOSPORINE was approved as cyclosporine by HIKMA on October 29th, 1999.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CYCLOSPORINE?
- What are the global sales for CYCLOSPORINE?
- What is Average Wholesale Price for CYCLOSPORINE?
Summary for CYCLOSPORINE
| US Patents: | 0 |
| Applicants: | 14 |
| NDAs: | 18 |
| Finished Product Suppliers / Packagers: | 10 |
| Raw Ingredient (Bulk) Api Vendors: | 89 |
| Clinical Trials: | 1,059 |
| Patent Applications: | 4,362 |
| Drug Prices: | Drug price information for CYCLOSPORINE |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for CYCLOSPORINE |
| What excipients (inactive ingredients) are in CYCLOSPORINE? | CYCLOSPORINE excipients list |
| DailyMed Link: | CYCLOSPORINE at DailyMed |
Recent Clinical Trials for CYCLOSPORINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Cord Blood Network | Phase 2 |
| Fred Hutchinson Cancer Center | Phase 2 |
| Assiut University | Phase 1 |
Pharmacology for CYCLOSPORINE
| Drug Class | Calcineurin Inhibitor Immunosuppressant |
| Mechanism of Action | Calcineurin Inhibitors Cytochrome P450 3A4 Inhibitors P-Glycoprotein Inhibitors |
Medical Subject Heading (MeSH) Categories for CYCLOSPORINE
Paragraph IV (Patent) Challenges for CYCLOSPORINE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| RESTASIS MULTIDOSE | Ophthalmic Emulsion | cyclosporine | 0.05% | 050790 | 1 | 2014-01-13 |
US Patents and Regulatory Information for CYCLOSPORINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apotex | CYCLOSPORINE | cyclosporine | CAPSULE;ORAL | 065040-001 | May 9, 2002 | AB2 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Mylan | CYCLOSPORINE | cyclosporine | EMULSION;OPHTHALMIC | 205894-001 | Feb 2, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Dr Reddys Labs Sa | CYCLOSPORINE | cyclosporine | SOLUTION;ORAL | 065054-001 | Dec 18, 2001 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Dr Reddys Labs Sa | CYCLOSPORINE | cyclosporine | CAPSULE;ORAL | 065044-001 | Dec 20, 2000 | AB1 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Apotex | CYCLOSPORINE | cyclosporine | CAPSULE;ORAL | 065040-002 | May 9, 2002 | AB2 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Sandoz | CYCLOSPORINE | cyclosporine | CAPSULE;ORAL | 065017-001 | Jan 13, 2000 | AB1 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Teva Pharms Usa Inc | CYCLOSPORINE | cyclosporine | EMULSION;OPHTHALMIC | 203880-001 | Dec 14, 2023 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
